Im very happy with my progress
AOD-9604 vs Alternatives Compared to GHRH analogs such as tesamorelin or CJC-1295, which act upstream by stimulating pituitary GH release and downstream IGF-1, AOD-9604 operates further down the pathway with a narrower receptor footprint
AOD9604 Phase IIb obesity trial results and program termination announcement
What the Research Says About Safety Clinical studies on AOD9604 indicate that the peptide is generally welltolerated: In human trials, no significant adverse effects were reported at doses up to 1 mg/day (safety summary) Unlike growth hormone therapies, AOD9604 does not meaningfully elevate IGF1 levels (human data), which may reduce the risk of unwanted growthrelated side effects
Selectivity and Safety Profile One of the most important characteristics of 5-amino-1MQ is its exceptional selectivity for the NNMT enzyme
If not deemed appropriate, you will be immediately refunded